Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of Ampligen in combination with atezolizumab for the treatment of advanced pancreatic cancer

Trial Profile

A clinical trial of Ampligen in combination with atezolizumab for the treatment of advanced pancreatic cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2018

At a glance

  • Drugs Atezolizumab (Primary) ; Rintatolimod (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Nov 2018 According to a Hemispherx Biopharma media release, Dr. K. Klute, PI, the University of Nebraska Medical Center is currently working on the study design and budget details.
    • 29 Oct 2018 New trial record
    • 22 Oct 2018 According to a Hemispherx Biopharma media release, the company in collaboration with the University of Nebraska Medical Center (UNMC) is planning this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top